U.S. FDA says some data testing Novartis' $2 million gene therapy was manipulated
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
PTC Therapeutics (PTCT) Misses Q2 EPS by 17c, Revenues Beat
August 6, 2019 5:25 PM EDTPTC Therapeutics (NASDAQ: PTCT) reported Q2 EPS of ($0.75), $0.17 worse than the analyst estimate of ($0.58). Revenue for the quarter came in at $85.5 million versus the consensus estimate of $78.64 million.
Second quarter 2019 financial highlights:
Total revenues were $85.5 million for the second quarter of 2019, compared to $68.7 million for the second quarter of 2018.Translarna net product revenues were $57.8 million for the second quarter of 2019, compared to $47.8 million for the second quarter of 2018. These results reflect the expanded commercialization of Translarna.Emflaza net product revenues were $27.6 million for the second quarter of 2019, compared to... More